Nastech Begins Dose-Ranging Obesity Nasal Spray Study
Posted on: Tuesday, 15 August 2006, 15:01 CDT
Nastech Pharmaceutical Company has initiated a dose-ranging study designed to evaluate the pharmacokinetics, efficacy and safety of various doses of the company's obesity nasal spray, PYY(3-36).
Because PYY is a protein, initial studies focused on PYY delivery by injection. Utilizing its proprietary drug delivery technology, however, Nastech has developed a nasal spray formulation of PYY as a unique, non-invasive treatment option for obesity.
The objective of the dose-ranging study of PYY(3-36) is to identify a dose or doses that would be appropriate for further study in a long-term phase II efficacy and safety clinical trial.
The study design is a double blind, cross-over test of multiple doses of PYY(3-36) nasal spray in 12 obese subjects. The study includes intravenous (IV) PYY and placebo treatment arms. The purpose of the intravenous arms is to confirm the pharmacodynamics of IV PYY, which in three prior studies has demonstrated an approximate 30% reduction of caloric intake at the following meal.
Subjects will be randomized to each treatment arm with approximately one week between treatments. A goal of the study is to identify nasal spray doses that result in similar caloric reduction to the intravenous dose. It is expected that this study will be completed during the fourth quarter 2006 and with a budget of approximately $400,000.
Source: Datamonitor
Related Articles
- Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
- Inspire Initiates Phase 3 Trial of Epinastine Nasal Spray for Allergic Rhinitis
- Alcon Amends NDA for Patanase(R) Nasal Spray
- Inspire to Advance Epinastine Nasal Spray to Phase 3
- Nastech Initiates Dose Ranging Study of PYY(3-36) Nasal Spray for Obesity
- ALTANA Submitted New Drug Applications for Ciclesonide Nasal Spray in the U.S. And Canada
- Alcon Presents New Clinical Data and Provides Regulatory Update on PATANASE(R) Nasal Spray
- Upsher-Smith Launches NEW Fortical(R) Nasal Spray for Postmenopausal Osteoporosis
- Nastech Pharmaceutical Company Inc. Announces Initiation of Clinical Trial for Investigational PYY3-36 Nasal Spray Under Co-Development and Co-Promotion Alliance With Merck & Co., Inc.
 |
 |
User Comments (0)
RSS Feeds